a nonsignificant trendP = 0.28
A post hoc analysis of the MI events in the LEADER trial showed a nonsignificant trend toward less CV death due to MI events in patients taking liraglutide versus placebo (4.7 vs. 6.7%, P = 0.28) ( 46 ).
A post hoc analysis of the MI events in the LEADER trial showed a nonsignificant trend toward less CV death due to MI events in patients taking liraglutide versus placebo (4.7 vs. 6.7%, P = 0.28) ( 46 ).
Breast, colon, and pancreatic cancers trended toward a protective effect but fell just short of statistical significance ( 16 ).